Analysts' ratings for VYNE Therapeutics (NASDAQ:VYNE) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table provides a quick overview of their recent ...
Vyne Therapeutics Inc. VYNE shares are trading higher Monday after the company announced a private placement of $88 million and positive data from its Phase 1b trial. In addition to the $88 million ...
VYNE Therapeutics Inc. (VYNE) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...
FDA places clinical hold on VYNE’s Phase 1b trial of VYN202 due to testicular toxicity seen in preclinical dog study. VYNE halts enrollment and dosing in psoriasis study; no serious adverse events ...
VYNE Therapeutics (VYNE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Dolezal from LifeSci Capital upgraded the rating on the stock ...
) has been revised to $3.32 / share. This is a decrease of 22.00% from the prior estimate of $4.25 dated September 10, 2025. The price target is an average of many targets provided by analysts. The ...
Detailed price information for Vyne Therapeutics Inc (VYNE-Q) from The Globe and Mail including charting and trades.
Detailed price information for Vyne Therapeutics Inc (VYNE-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results